iNOS (phospho-Tyr-1055) Blocking Peptide
€155.00
In stock
SKU
ECM-NX4095
Background:
Nitric oxide synthases (NOS), the enzymes responsible for synthesis of NO, are homodimers whose monomers are themselves two fused enzymes: a cytochrome reductase and a cytochrome that requires three cosubstrates (L-arginine, NADPH, and oxygen) and five cofactors or prosthetic groups (FAD, FMN, calmodulin, tetrahydrobiopterin, and heme). Several distinct NOS isoforms are produced from three distinct genes, inducible NOS (iNOS, NOS-II), neuronal NOS (bNOS, NOS-I), and endothelial NOS (eNOS, ecNOS, NOS-III). The inducible form of NOS, iNOS, is Ca2+ independent and is expressed in a broad range of cell types in response to stimulation with cytokines and exposure to microbial products. Phosphorylation of iNOS may regulate its activity and stability. Src kinase-induced phosphorylation of Tyr-1055 in iNOS reduces proteasomal degradation of iNOS leading to increased NO production. Thus, phosphorylation may be an additional control for regulating iNOS activity in response to inflammatory conditions.
Sequence: Phospho-iNOS (Tyr-1055) synthetic peptide corresponds to amino acids surrounding Tyr-1055 in human iNOS. This sequence is well conserved in rat and mouse iNOS, and has some homology to the conserved sites in eNOS (Tyr-1087) and nNOS (Tyr-1326).
Specificity: The peptide is specifically recognized by anti-iNOS (Tyr-1055) phospho-specific antibody (NP4091) in ELISA, and has been shown to block the reactivity of NP4091 during Western blot. In addition, the peptide is recommended for use in blocking NP4091 reactivity in immunocytochemistry.
Buffer/Storage:
Blocking Peptide is supplied in 50µl phosphate-buffered saline and 0.05% sodium azide. Store at –20°C. Stable for 1 year.
Nitric oxide synthases (NOS), the enzymes responsible for synthesis of NO, are homodimers whose monomers are themselves two fused enzymes: a cytochrome reductase and a cytochrome that requires three cosubstrates (L-arginine, NADPH, and oxygen) and five cofactors or prosthetic groups (FAD, FMN, calmodulin, tetrahydrobiopterin, and heme). Several distinct NOS isoforms are produced from three distinct genes, inducible NOS (iNOS, NOS-II), neuronal NOS (bNOS, NOS-I), and endothelial NOS (eNOS, ecNOS, NOS-III). The inducible form of NOS, iNOS, is Ca2+ independent and is expressed in a broad range of cell types in response to stimulation with cytokines and exposure to microbial products. Phosphorylation of iNOS may regulate its activity and stability. Src kinase-induced phosphorylation of Tyr-1055 in iNOS reduces proteasomal degradation of iNOS leading to increased NO production. Thus, phosphorylation may be an additional control for regulating iNOS activity in response to inflammatory conditions.
Sequence: Phospho-iNOS (Tyr-1055) synthetic peptide corresponds to amino acids surrounding Tyr-1055 in human iNOS. This sequence is well conserved in rat and mouse iNOS, and has some homology to the conserved sites in eNOS (Tyr-1087) and nNOS (Tyr-1326).
Specificity: The peptide is specifically recognized by anti-iNOS (Tyr-1055) phospho-specific antibody (NP4091) in ELISA, and has been shown to block the reactivity of NP4091 during Western blot. In addition, the peptide is recommended for use in blocking NP4091 reactivity in immunocytochemistry.
Buffer/Storage:
Blocking Peptide is supplied in 50µl phosphate-buffered saline and 0.05% sodium azide. Store at –20°C. Stable for 1 year.
| Is Featured? | No |
|---|
Write Your Own Review